Chalcone-imidazolone conjugates induce apoptosis through DNA damage pathway by affecting telomeres

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Ramaiah, M J ^a   Pushpavalli, SNCVL ^a   Krishna, G R ^a   Sarma, Pranjal ^a   Mukhopadhyay, Debasmita ^a   Kamal, Ahmed ^a   Bhadra, Utpal ^b   Bhadra, Manika P ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CHALCONE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA; IMIDAZOLE DERIVATIVE; IMIDAZOLONE; PROTEIN BAX; PROTEIN P21; PROTEIN P53; PROTEIN P53BP1; RETINOBLASTOMA PROTEIN; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG CONJUGATION; HUMAN; HUMAN CELL; IMMUNOLOCALIZATION; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TELOMERE;

EID: 79955017197     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-11     Document Type: Article

References (39)

1. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer epidemiology 2009, 33:315-318. 10.1016/j.canep.2009.10.003, 19896917.
2. Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci 2004, 1028:150-156. 10.1196/annals.1322.016, 15650241.
3. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004, 23:2797-808. 10.1038/sj.onc.1207532, 15077143.
4. Stein GH, Drullinger LF, Soulard A, Dulic V. Differential roles of cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 1999, 19:2109-2117. 84004, 10022898.
5. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004, 23:2919-33. 10.1038/sj.onc.1207518, 15077154.
6. Palm W, de Lange T. How Shelterin protects mammalian telomeres. Annu Rev Genet 2008, 42:301-334. 10.1146/annurev.genet.41.110306.130350, 18680434.
7. Van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998, 92:401-413. 10.1016/S0092-8674(00)80932-0, 9476899.
8. Celli GB, de Lange T. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol 2005, 7:712-718. 10.1038/ncb1275, 15968270.
9. Nijjar T, Bassett E, Garbe J, Takenaka Y, Stampfer MR, Gilley D, Yaswen P. Accumalation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells. Oncogene 2005, 24:3369-3376. 10.1038/sj.onc.1208482, 15735711.
10. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. P53 and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999, 283:1321-1325. 10.1126/science.283.5406.1321, 10037601.
11. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 2002, 295:2446-2449. 10.1126/science.1069523, 11923537.
12. Biroccio A, Rizz A, Elli R, Koering CE, Belleville A, Benassi B, Leonetti C, Stevens MFG, D'Incalci M, Zupi G, Gilson E. TRF2 inhibition triggers apoptosis and reduces tumorigenicity of human melanoma cells. Eur J Cancer 2006, 42:1881-1888. 10.1016/j.ejca.2006.03.010, 16750909.
13. Von Zglinicki T, Saretzki G, Ladhoff J, d'Adda di Fagagna F, Jackson SP. Human cell senescence as a DNA damage response. Mech Aging Dev 2005, 126:111-117. 10.1016/j.mad.2004.09.034, 15610769.
14. Shiloh Y. ATM and related protein kinases: Safe guarding genome integrity. Nat Rev Cancer 2003, 3:155-168. 10.1038/nrc1011, 12612651.
15. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. Toward maintaining the genome: DNA damage and replication check points. Annu Rev Genet 2002, 36:617-656. 10.1146/annurev.genet.36.060402.113540, 12429704.
16. Lou Z, Chini CC, Minter-Dykhouse K, Chen J. Mediator DNA damage check point protein1 regulates BRCA1 localization and phosphorylation in DNA damage check point control. J Biol Chem 2003, 278:13599-602. 10.1074/jbc.C300060200, 12611903.
17. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004, 23:2919-33. 10.1038/sj.onc.1207518, 15077154.
18. Mc Gown AT, Fox BW. Differential cytotoxicity of Combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. Cancer Chemother Pharmacol 1990, 26:79-81. 10.1007/BF02940301, 2322992.
19. Petitt GR, Temple C, Narayanan VL, Varma R, Simpson MJ. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anti-cancer Drug Des 1995, 10:299-309.
20. Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Invest Drugs 2004, 13:1171-1182.
21. Ducki S, Forrest R, Hadfield JA, Kendall A, Lawrence NJ, Mc Gown AT, Rennison D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg Med Chem Lett 1998, 8:1051-1056. 10.1016/S0960-894X(98)00162-0, 9871706.
22. Lawrence NJ, Mc Gown AT, Ducki S, Hadfield JA. The interaction of chalcones with tubulin. Anticancer Drug Des 2000, 15:135-141.
23. Nielsen SF, Boesen T, Larsen M, Schonnig K, Kromann H. Antibacterial chalcones-bioisosteric replacement of the 4-hydroxy group. Bioorg Med Chem 2004, 12:3047-3054. 10.1016/j.bmc.2004.03.071, 15142563.
24. Kamal A, Ramakrishna G, Raju P, Viswanath A, Ramaiah MJ, Balakishan G, Pal-Bhadra M. Synthesis and anti-cancer activity of chalcone linked imidazolones. Bioorg Med Chem Lett 2010, 20:4865-9. 10.1016/j.bmcl.2010.06.097, 20637611.
25. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin1 beta converting enzyme like proteases. Proc Natl Acad Sci 1996, 93:14559-14563. 10.1073/pnas.93.25.14559, 26172, 8962091.
26. Fattman CL, An B, Dou PQ. Characterization of interior Cleavage of Retinoblastoma Protein in apoptosis. J Cell Biochem 1997, 67:399-408. 10.1002/(SICI)1097-4644(19971201)67:3<399::AID-JCB11>3.0.CO;2-8, 9361194.
27. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.
28. Ithahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur J Biochem 2001, 268:2784-2791. 10.1046/j.1432-1327.2001.02228.x, 11358493.
29. Jaiswal AS, Multani AS, Pathak S, Narayan S. N-Methyl-N'-nitro-N-nitrosoguanidine-induced senescence-like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA. Mol cancer 2004, 3:1-13. 10.1186/1476-4598-3-1, 324565, 14723797.
30. Chen J, Blasco M, Greider C. Secondary structure of vertebrate telomerase RNA. Cell 2000, 100:503-514. 10.1016/S0092-8674(00)80687-X, 10721988.
31. Takai H, Smogorzewska A, de lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003, 3:1549-1556.
32. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, VonZglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198. 10.1038/nature02118, 14608368.
33. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC. BRCA1 regulates the G2/M check point by activating Chk1 kinase up on DNA damage. Nat Genet 2002, 30:285-289. 10.1038/ng837, 11836499.
34. Blagosklonny MV. Targeting cancer cells by exploring their resistance. Trends Mol Med 2003, 9(7):307-312. 10.1016/S1471-4914(03)00111-4, 12900218.
35. Rodriguez-nieto S, Zhivotovsky B. Role of alterations in apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006, 12(34):4411-4425. 10.2174/138161206779010495, 17168751.
36. Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407:770-776. 10.1038/35037710, 11048727.
37. Wyllie AH. Apoptosis: an overview. Br Med Bull 1997, 53:451-465.
38. Harris SL, Levin AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24:2899-2908. 10.1038/sj.onc.1208615, 15838523.
39. Herbig U, Jobling WA, Chen BPC, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53 and p21CIP1, but not p16INK4a. Mol Cell 2004, 14:501-513. 10.1016/S1097-2765(04)00256-4, 15149599.